<i>ABCG2</i> and <i>SLCO1B1</i> gene polymorphisms in the Croatian population-Reference-Cited by-同舟云学术

ABCG2 and SLCO1B1 gene polymorphisms in the Croatian population

Published:2022-11-17 Issue:7-8 Volume:49 Page:323-331
ISSN:0301-4460
Container-title:Annals of Human Biology
language:en
Short-container-title:Annals of Human Biology

Author:

Božina Tamara¹,Ganoci Lana²,Karačić Ena³,Šimičević Livija²,Vrkić-Kirhmajer Majda⁴,Klarica-Domjanović Iva⁵,Križ Tena⁶,Sertić Zrinka⁷,Božina Nada⁸

Affiliation:

1. Department of Medical Chemistry, Biochemistry, and Clinical Chemistry, University of Zagreb School of Medicine, Zagreb, Croatia

2. Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia

3. Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

4. Department of Cardiovascular Diseases Zagreb, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Croatia

5. Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia

6. Department of Ophthalmology, University Hospital Centre “Sestre milosrdnice”, Zagreb, Croatia

7. Department of Emergency Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

8. Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia

Funder

Croatian Science Foundation for the Installation Research Projects

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Genetics,Aging,Physiology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03014460.2022.2140826

Reference98 articles.

1. [CPIC] Clinical Pharmacogenetics Implementation Consortium 2022. [accessed 2022 Feb 22]. www.cpicpgx.org/.

2. [DPWG] Dutch Pharmacogenetics Working Group 2022. Pharmacogenetic recommendation text 20220201. [accessed 2022 March 23]. https://www.knmp.nl/media/1058.

3. [EMA] European Medicines Agency 2012., London, UK: guideline on the investigation of drug interactions CPMP/EWP/560/95/rev. 1 Corr. 2**. [accessed 2022 March 22]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.

4. [FDA] 2017. US Food and Drug Administration: guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. [accessed 2022 March 22]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.

5. [FDA] US Food and Drug Administration 2021. Table of pharmacogenomic biomarkers in drug labels. [accessed 20022 March 22]. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review;Diabetology;2024-09-03